quinazolines has been researched along with Polycythemia Vera in 36 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.78) | 18.7374 |
| 1990's | 3 (8.33) | 18.2507 |
| 2000's | 18 (50.00) | 29.6817 |
| 2010's | 12 (33.33) | 24.3611 |
| 2020's | 2 (5.56) | 2.80 |
| Authors | Studies |
|---|---|
| Fleischman, A; Gotlib, J; Heaney, M; Hoffman, R; Kremyanskaya, M; Kuykendall, A; Mascarenhas, J; Mesa, R; O'Connell, C; Podoltsev, N; Rippel, N; Shammo, JM; Tremblay, D; Yacoub, A; Zubizarreta, N | 1 |
| Besses, C; Blau, IW; Dong, T; Durrant, S; Francillard, N; Griesshammer, M; Harrison, CN; Hino, M; Kiladjian, JJ; Kirito, K; Masszi, T; Mesa, R; Miller, CB; Moiraghi, B; Pane, F; Passamonti, F; Rosti, V; Rumi, E; Vannucchi, AM; Verstovsek, S; Wroclawska, M; Zachee, P | 1 |
| Begna, KH; Christopher Hook, C; Elliott, MA; Gangat, N; Hanson, CA; Ketterling, RP; Pardanani, A; Patnaik, MM; Szuber, N; Tefferi, A; Vallapureddy, RR; Wolanskyj, AP | 1 |
| Ahn, IE; Natelson, E; Rice, L | 1 |
| Newberry, KJ; Sever, M; Verstovsek, S | 1 |
| De Raeve, H; Gadisseur, A; Michiels, JJ; Pich, A | 1 |
| Miyamoto, T; Yoshimoto, G | 1 |
| Al-Kali, A; Cherry, M; Ghabache, B; Khawandanah, M; Ozer, H; Selby, G; Srour, S; Zhao, ZJ | 1 |
| Bang, SM; Kim, JW; Kim, SH; Kim, YJ; Lee, JO; Lee, JS; Lee, KW; Lim, Y | 1 |
| Hoffman, R; Kremyanskaya, M; Mascarenhas, J | 1 |
| Aksu, S; Büyükaşık, Y; Eliaçık, E; Göker, H; Haznedaroğlu, İC; Işık, A; Özcebe, OI; Sayınalp, N; Üner, A | 1 |
| Besses, C; Burgaleta, C; Hernández-Boluda, JC; Hernández-Rivas, JM; Jiménez Velasco, A; Martínez Lopez, J; Pérez Encinas, M; Raya, JM; Vicente, V | 1 |
| Barbui, T; Finazzi, G | 1 |
| Anastasiadis, A; Bourikas, G; Christoforidou, A; Goutzouvelidis, A; Kaloutsi, V; Kotsianidis, I; Margaritis, D; Pantelidou, D; Spanoudakis, E; Tsatalas, C | 1 |
| Dai, Y; Hoffman, R; Ishii, T; Mascarenhas, J; Najfeld, V; Sozer, S; Wang, J; Wisch, N; Xu, M; Zhang, W; Zhao, ZJ | 1 |
| Beer, PA; Green, AR | 1 |
| Buliková, A; Doubek, M; Dulícek, P; Hlusí, A; Kissová, J; Korístek, Z; Ovesná, P; Pavlík, T; Penka, M; Pospísilová, D; Schwarz, J | 1 |
| Li, Y; Ren, YY; Zhang, LY | 1 |
| Gilbert, HS | 2 |
| Campbell, PJ; Curtin, N; Green, AR; Vassiliou, GS | 1 |
| Barbui, T | 1 |
| Jurgens, DJ; Moreno-Aspitia, A; Tefferi, A | 1 |
| Fu, X; Ho, WT; Ishii, T; Li, Q; Li, Z; Xing, S; Xu, M; Zhao, ZJ | 1 |
| Birgegård, G; Engström-Laurent, A; Hultdin, M; Lundström, B; Samuelsson, J; Sundström, G; Wahlin, A | 1 |
| Brychtová, Y; Bubeník, B; Cerná, O; Doubek, M; Dulícek, P; Dusek, L; Hadacová, I; Hlusí, A; Hochová, I; Kissová, J; Lhotanová, T; Micaníková, M; Pavlík, T; Penka, M; Pospísilová, D; Pytlík, R; Schützová, M; Schwarz, J; Seghetová, J; Szotkowski, T; Voglová, J; Volková, Z; Vozobulová, V; Vránová, M; Zapletal, O | 1 |
| Bareford, D; Buck, G; Campbell, PJ; East, CL; Erber, WN; Green, AR; Harrison, CN; Paul, B; Wheatley, K; Wilkins, BS | 1 |
| Elliott, MA; Silverstein, MN; Solberg, LA; Tefferi, A | 1 |
| Sréter, L | 1 |
| Silverstein, MN; Tefferi, A | 1 |
| Barbui, T; Finazzi, G; Fuchtman, SM; Kutti, J; Michiels, JJ; Rain, JD; Silver, RT; Tefferi, A; Thiele, J | 1 |
| James, CW | 1 |
| Hehlmann, R; Lengfelder, E | 1 |
| Bennett, M; Grunwald, AJ | 1 |
| Solberg, LA | 1 |
| Fleming, JS; Knight, RC; Petitt, RM; Schacter, LP; Silverstein, MN; Solberg, LA | 1 |
15 review(s) available for quinazolines and Polycythemia Vera
| Article | Year |
|---|---|
Therapeutic options for patients with polycythemia vera and essential thrombocythemia refractory/resistant to hydroxyurea.
Topics: Antineoplastic Agents; Busulfan; Disease Management; Drug Resistance; Histone Deacetylase Inhibitors; Humans; Hydroxyurea; Interferon-alpha; Janus Kinase 2; Pipobroman; Platelet Aggregation Inhibitors; Polycythemia Vera; Protein Kinase Inhibitors; Quinazolines; Thrombocythemia, Essential; Treatment Outcome | 2014 |
[Treatment strategy for myeloproliferative neoplasms].
Topics: Adrenal Cortex Hormones; Aspirin; Calreticulin; Carbamates; Clinical Trials as Topic; Drug Therapy, Combination; Hematopoietic Stem Cell Transplantation; Humans; Hydroxyurea; Immunosuppressive Agents; Janus Kinase 2; Molecular Targeted Therapy; Mutation; Nitriles; Platelet Aggregation Inhibitors; Polycythemia Vera; Primary Myelofibrosis; Prognosis; Pyrazoles; Pyrimidines; Quinazolines; Receptors, Thrombopoietin; Thalidomide; Thrombocythemia, Essential | 2014 |
Anagrelide hydrochloride and ruxolitinib for treatment of polycythemia vera.
Topics: Aspirin; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Hydroxyurea; Interferon-alpha; Nitriles; Platelet Aggregation Inhibitors; Polycythemia Vera; Polyethylene Glycols; Pyrazoles; Pyrimidines; Quinazolines | 2015 |
Pharmacobiological Approach for the Clinical Development of Ruxolitinib in Myeloproliferative Neoplasms.
Topics: Bone Marrow; Combined Modality Therapy; Disease Progression; Female; Fibrosis; Humans; Hydroxyurea; Janus Kinase 2; Leukapheresis; Middle Aged; Myeloproliferative Disorders; Nitriles; Phlebotomy; Point Mutation; Polycythemia Vera; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Quinazolines; Splenectomy; Splenomegaly | 2015 |
Evidence and expertise in the management of polycythemia vera and essential thrombocythemia.
Topics: Aspirin; Humans; Hydroxyurea; Interferon-alpha; Janus Kinase 2; Mutation; Phlebotomy; Polycythemia Vera; Quinazolines; Risk Factors; Survival Analysis; Thrombocythemia, Essential | 2008 |
Pathogenesis and management of essential thrombocythemia.
Topics: Acute Disease; Aged; Aspirin; Clone Cells; Disease Management; Disease Progression; Humans; Hydroxyurea; Interferon-alpha; Janus Kinase 2; Leukemia, Myeloid; Middle Aged; Models, Biological; Mutation, Missense; Polycythemia Vera; Primary Myelofibrosis; Prognosis; Protein Kinase Inhibitors; Quinazolines; Thrombocythemia, Essential; Thrombophilia | 2009 |
Modern treatment strategies in polycythemia vera.
Topics: Age Factors; Antineoplastic Agents; Drug Therapy, Combination; Humans; Hydroxyurea; Interferon-alpha; Phlebotomy; Platelet Aggregation Inhibitors; Polycythemia Vera; Quinazolines; Risk Factors | 2003 |
Management of the myeloproliferative disorders : distinguishing data from dogma.
Topics: Abnormalities, Drug-Induced; Adult; Aged; Anticoagulants; Contraindications; Female; Humans; Hydroxyurea; Interferon-alpha; Male; Middle Aged; Myeloproliferative Disorders; Phlebotomy; Polycythemia Vera; Pregnancy; Pregnancy Complications, Hematologic; Prognosis; Quinazolines; Randomized Controlled Trials as Topic; Thrombocythemia, Essential; Thrombophilia | 2004 |
The leukemia controversy in myeloproliferative disorders: is it a natural progression of disease, a secondary sequela of therapy, or a combination of both?
Topics: Age Factors; Aged; Antineoplastic Agents, Alkylating; Antiviral Agents; Disease Progression; Female; Humans; Hydroxyurea; Interferon-alpha; Leukemia; Male; Middle Aged; Platelet Aggregation Inhibitors; Polycythemia Vera; Quinazolines; Risk Factors; Thrombocythemia, Essential; Thrombosis | 2004 |
New drugs in essential thrombocythemia and polycythemia vera.
Topics: Antineoplastic Agents; Fibrinolytic Agents; Humans; Interferon alpha-2; Interferon-alpha; Polycythemia Vera; Quinazolines; Recombinant Proteins; Thrombocytosis | 1997 |
Treatment of polycythaemia vera and essential thrombocythaemia.
Topics: Adult; Aged; Aspirin; Chlorambucil; Disease Progression; Female; Hemorrhage; Humans; Hydroxyurea; Interferon-alpha; Leukemia, Myeloid; Leukemia, Radiation-Induced; Male; Middle Aged; Phlebotomy; Phosphorus Radioisotopes; Pipobroman; Polycythemia Vera; Primary Myelofibrosis; Prospective Studies; Quinazolines; Thrombocythemia, Essential; Thrombosis | 1998 |
Diagnosis and treatment of polycythemia vera and possible future study designs of the PVSG.
Topics: Blood Platelets; Forecasting; Humans; Hydroxyurea; Interferon-alpha; Megakaryocytes; Platelet Aggregation Inhibitors; Polycythemia Vera; Prospective Studies; Quinazolines; Randomized Controlled Trials as Topic | 2000 |
[Polycythemia vera: current status of therapy].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Bloodletting; Clinical Trials as Topic; Fibrinolytic Agents; Humans; Hydroxyurea; Interferon-alpha; Leukemia; Middle Aged; Phlebotomy; Pipobroman; Platelet Aggregation Inhibitors; Polycythemia Vera; Prognosis; Prospective Studies; Quinazolines; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Factors; Thromboembolism | 2000 |
Diagnosis and treatment of thrombocythemia in myeloproliferative disorders.
Topics: Enzyme Inhibitors; Humans; Hydroxyurea; Immunologic Factors; Interferon-alpha; Polycythemia Vera; Quinazolines; Thrombocytosis | 2001 |
Therapeutic options for essential thrombocythemia and polycythemia vera.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Aspirin; Busulfan; Fibrinolytic Agents; Humans; Hydroxyurea; Immunologic Factors; Immunosuppressive Agents; Interferon-alpha; Nucleic Acid Synthesis Inhibitors; Phosphorus Radioisotopes; Polycythemia Vera; Quinazolines; Risk Assessment; Thrombocytosis | 2002 |
4 trial(s) available for quinazolines and Polycythemia Vera
| Article | Year |
|---|---|
Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Drug Therapy, Combination; Fibrinolytic Agents; Follow-Up Studies; Humans; Hydroxyurea; Interferon alpha-2; Interferon-alpha; Nitriles; Pipobroman; Polycythemia Vera; Polyethylene Glycols; Prognosis; Pyrazoles; Pyrimidines; Quinazolines; Recombinant Proteins; Survival Rate; Time Factors | 2020 |
Erlotinib is not effective in patients with JAK2V617F-positive polycythemia vera.
Topics: Adult; Aged; Amino Acid Substitution; Antineoplastic Agents; Drug-Related Side Effects and Adverse Reactions; Erlotinib Hydrochloride; Female; Humans; Janus Kinase 2; Male; Middle Aged; Phenylalanine; Polycythemia Vera; Quinazolines; Treatment Outcome; Valine | 2015 |
Progression of bone marrow fibrosis in patients with essential thrombocythemia and polycythemia vera during anagrelide treatment.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Disease Progression; Female; Fibrinolytic Agents; Humans; Hyaluronic Acid; Male; Middle Aged; Polycythemia Vera; Primary Myelofibrosis; Prognosis; Prospective Studies; Quinazolines; Reticulin; Thrombocythemia, Essential; Thrombocytosis | 2007 |
Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes.
Topics: Adult; Antineoplastic Agents; Aspirin; Biopsy; Blood Cell Count; Drug Therapy, Combination; Hematology; Humans; Hydroxyurea; Megakaryocytes; Observer Variation; Pathology, Clinical; Platelet Aggregation Inhibitors; Polycythemia Vera; Primary Myelofibrosis; Prospective Studies; Quinazolines; Thrombocytosis | 2008 |
17 other study(ies) available for quinazolines and Polycythemia Vera
| Article | Year |
|---|---|
Anagrelide for platelet-directed cytoreduction in polycythemia vera: Insights into utility and safety outcomes from a large multi-center database.
Topics: Cytoreduction Surgical Procedures; Humans; Polycythemia Vera; Quinazolines; Thrombocythemia, Essential; Thrombocytosis; Thrombosis | 2022 |
Decreased survival and increased rate of fibrotic progression in essential thrombocythemia chronicled after the FDA approval date of anagrelide.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bone Marrow; Disease Progression; Disease-Free Survival; Drug Approval; Female; Fibrosis; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Mortality; Platelet Aggregation Inhibitors; Polycythemia Vera; Primary Myelofibrosis; Prognosis; Proportional Hazards Models; Quinazolines; Retrospective Studies; Severity of Illness Index; Thrombocythemia, Essential; Thrombosis; Treatment Outcome; Young Adult | 2019 |
Successful long-term treatment of Philadelphia chromosome-negative myeloproliferative neoplasms with combination of hydroxyurea and anagrelide.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Hydroxyurea; Male; Middle Aged; Myeloproliferative Disorders; Philadelphia Chromosome; Polycythemia Vera; Quinazolines; Retrospective Studies; Thrombocythemia, Essential; Thrombosis | 2013 |
Essential differences in clinical and bone marrow features in BCR/ABL-positive thrombocythemia compared to thrombocythemia in the BCR/ABL-negative myeloproliferative neoplasms essential thrombocythemia and polycythemia vera.
Topics: Aged; Alleles; Benzamides; Biopsy; Bone Marrow; Diagnosis, Differential; Drug Therapy, Combination; Female; Fusion Proteins, bcr-abl; Humans; Hydroxyurea; Imatinib Mesylate; Janus Kinase 2; Male; Middle Aged; Mutation; Myeloproliferative Disorders; Piperazines; Platelet Count; Polycythemia Vera; Pyrimidines; Quinazolines; Thrombocythemia, Essential; Treatment Outcome | 2015 |
Prediction of thrombotic and hemorrhagic events during polycythemia vera or essential thrombocythemia based on leukocyte burden.
Topics: Adult; Aged; Aged, 80 and over; Area Under Curve; Blood Cell Count; Comorbidity; Databases, Factual; Female; Follow-Up Studies; Hemorrhage; Hemorrhagic Disorders; Humans; Hydroxyurea; Leukocyte Count; Male; Middle Aged; Phlebotomy; Platelet Aggregation Inhibitors; Polycythemia Vera; Prognosis; Quinazolines; Retrospective Studies; Risk Factors; Thrombocythemia, Essential; Thrombophilia; Thrombosis; Young Adult | 2015 |
Current opinion and consensus statement regarding the diagnosis, prognosis, and treatment of patients with essential thrombocythemia: a survey of the Spanish Group of Ph-negative Myeloproliferative Neoplasms (GEMFIN) using the Delphi method.
Topics: Bone Marrow Examination; Delphi Technique; Diagnosis, Differential; Disease Management; DNA Mutational Analysis; Humans; Hydroxyurea; Janus Kinase 2; Mutation, Missense; Platelet Count; Polycythemia Vera; Prognosis; Quinazolines; Receptors, Thrombopoietin; Risk Assessment; Surveys and Questionnaires; Thrombocythemia, Essential; Thrombophilia | 2016 |
Hydroxyurea and anagrelide combination therapy in patients with chronic myeloproliferative diseases resistant or intolerant to monotherapy.
Topics: Adult; Aged; Aged, 80 and over; Drug Resistance; Drug Therapy, Combination; Female; Humans; Hydroxyurea; Male; Middle Aged; Polycythemia Vera; Quinazolines; Thrombocythemia, Essential | 2008 |
Involvement of mast cells by the malignant process in patients with Philadelphia chromosome negative myeloproliferative neoplasms.
Topics: Antigens, CD34; Cells, Cultured; Erlotinib Hydrochloride; Humans; Janus Kinase 2; Mast Cells; Mutation; Polycythemia Vera; Primary Myelofibrosis; Quinazolines; Receptors, Thrombopoietin; Thrombocythemia, Essential | 2009 |
[Essential thrombocythaemia and other myeloproliferative disorders with thrombocythaemia treated with Thromboreductin. A report from the database of register for the 1st quarter of 2010].
Topics: Adult; Aged; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Count; Polycythemia Vera; Primary Myelofibrosis; Quinazolines; Thrombocythemia, Essential | 2010 |
[Effect of erlotinib on proliferation and differentiation of JAK2V617F-positive cells in vitro].
Topics: Cell Differentiation; Cell Proliferation; Cells, Cultured; Erlotinib Hydrochloride; Hematopoietic Stem Cells; Humans; Janus Kinase 2; Polycythemia Vera; Quinazolines | 2012 |
Anagrelide-associated cardiomyopathy in polycythemia vera and essential thrombocythemia.
Topics: Cardiomyopathies; Female; Humans; Platelet Aggregation Inhibitors; Polycythemia Vera; Quinazolines; Thrombocythemia, Essential | 2004 |
Erlotinib effectively inhibits JAK2V617F activity and polycythemia vera cell growth.
Topics: Amino Acid Substitution; Animals; Cell Line, Tumor; Cell Proliferation; Drug Delivery Systems; Enzyme Activation; Erlotinib Hydrochloride; Growth Inhibitors; Hematopoietic Stem Cells; Humans; Janus Kinase 2; Jurkat Cells; Mice; Phenylalanine; Polycythemia Vera; Protein Kinase Inhibitors; Quinazolines; Valine | 2007 |
[Essential thrombocytemia and other myeloproliferations with thrombocytemia in the data of the register of patients treated with Thromboreductin till the end of 2006].
Topics: Adult; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Myeloproliferative Disorders; Platelet Aggregation Inhibitors; Platelet Count; Polycythemia Vera; Quinazolines; Thrombocytosis | 2007 |
[Chronic myeloproliferative diseases].
Topics: Chronic Disease; Female; Fibrinolytic Agents; Humans; Interferons; Leukemia, Myeloid; Male; Myeloproliferative Disorders; Polycythemia Vera; Primary Myelofibrosis; Quinazolines; Thrombocythemia, Essential | 1998 |
Anagrelide-induced cardiomyopathy.
Topics: Cardiomyopathies; Female; Humans; Middle Aged; Platelet Aggregation Inhibitors; Polycythemia Vera; Quinazolines | 2000 |
Hydroxyurea and periodicity in myeloproliferative disease.
Topics: Adult; Aged; Antineoplastic Agents; Blood Cell Count; Busulfan; Female; Hemoglobins; Humans; Hydroxyurea; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Count; Lymphocytes; Male; Monocytes; Neutrophils; Periodicity; Platelet Count; Polycythemia Vera; Quinazolines | 2001 |
Anagrelide: a new drug for treating thrombocytosis.
Topics: Adult; Aged; Female; Hematopoietic Stem Cells; Humans; Male; Middle Aged; Myeloproliferative Disorders; Platelet Aggregation Inhibitors; Platelet Count; Polycythemia Vera; Quinazolines; Thrombocythemia, Essential; Thrombocytosis | 1988 |